More effective treatments for metastatic lung cancer remain a pressing clinical need.
Introduction
Lung cancer is the leading cause of cancer death worldwide. The major cause of treatment failure and mortality is cancer metastasis (1) (2) (3) . The cyclooxygenases (COX), key enzymes in the biosynthesis of prostaglandins, are potential mediators of metastasis. Overexpression of COX-2, an inducible form of COX, is frequently found in early and advanced lung cancer tissues and is associated with poor prognosis (4-7).
Elevated levels of tumor COX-2 and its metabolite prostaglandin E2 (PGE2) contribute to a decrease in E-cadherin, induction of tumor angiogenesis, augmentation of cancer motility and invasiveness, resistance to apoptosis, and suppression of antitumor immunity (5, 8, 9) .
The binding of PGE2 to one or more of its four G protein-coupled receptors, designated EP1, EP2, EP3, and EP4, has been shown to stimulate phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) and extracellular signal-regulated kinase 1/2 (ERK1/2) signaling and is implicated in cancer-cell growth and progression (8) (9) (10) (11) .
However, both the COX-2/PGE2 and PI3K/Akt signaling cascades exist in normal cells with pleiotropic functions and inhibition of these two important signaling pathways causes a variety of undesirable side-effects (12, 13) . One notorious example of the effects of the long-term use of COX-2 inhibitors is rofecoxib (Vioxx) which resulted in renal and cardiovascular system impairment and was withdrawn from the market in 2004 (14, 15) . Discovery of agents that target the downstream effector(s) of COX-2/PGE2 and PI3K/Akt signaling cascades is desirable to aid the development of therapeutics that have better selectivity and specificity and no severe adverse effects.
Another potential mediator of metastasis is migration inducing gene-7 (MIG- 7) protein (16) . Increase in MIG-7 mRNA is found in embryonic cytotrophoblast cells during placenta development as well as in more than 80% of tumor cells, but not found in 25 different normal tissues or in blood from normal subjects (16) (17) (18) .
Transduction of MIG-7 in carcinoma cells results in invasion by carcinoma cells in three-dimensional culture in vitro (17) . Stably expressing MIG-7-specific shRNA, on the other hand, reduces phosphorylation of Akt and ERK1/2 and attenuates membrane-type 1 matrix metalloproteinase (MT1-MMP) activity in endometrial carcinoma cell lines (19) . Whether or not this holds true for lung cancer has not been examined and functional association between MIG-7 and COX-2/PGE2 signaling in promoting lung cancer invasion/metastasis remains elusive.
In this study, we found that MIG-7 was functionally associated with COX-2/PGE2-induced lung cancer metastasis through phosphorylation of Akt and glycogen sythase kinase-3 β (GSK-3β), activation of β-catenin/TCF-4/LEF-1 signaling and decrease in the activity of protein phosphatase 2A (PP2A). The critical role of MIG-7 protein was further substantiated by examining its level in the human lung cancers as well as the effects of overexpressing MIG-7 on lung cancer cells in a xenograft mouse model. 
Materials and Methods

Materials
Immunoblotting, immunoprecipitation and gelatin zymographic analysis
Gelatinolytic activities of MMP-2 and MMP-9, immunoprecipitation and immunoblotting were performed as described previously (21, 22) .
Migration, invasion and anchorage-independent growth assays
In vitro migration, invasion and anchorage-independent growth assays were (23) .
Luciferase reporter assay
To examine transcriptional regulation of MIG7 promoters, genomic DNA was isolated from the A549 cell line and approximately 3 kb of the MIG7 promoter was amplified by PCR using the specific primers listed in Supplementary Table S1 (Sigma-Proligo) and subcloned into the pGL3-basic vector (Promega 
PP2A activity assay
Cellular PP2A activity was assayed using a PP2A immunoprecipitation phosphatase assay kit (Upstate) according to the manufacturer's instructions. S5E ).
Preparation of pCMV-GFP
Experimental xenograft murine metastasis model
Male SCID mice (n = 9/group) were implanted with 50 µl RPMI medium (vehicle) or 1 × 10 6 /50 µl lung tumor cells on day 0 by lateral tail vein injection. Metastatic progression was monitored weekly and quantified using a noninvasive bioluminescence IVIS Imaging System (Xenogen, Alameda, CA) as described previously (22) . Thirty-five days after injection, three mice were killed for necropsy and the other 6 mice were kept for survival studies. The percentage of animal survival in each group was routinely recorded.
Immunohistochemistry, histopathology examination and assessment of MIG-7 protein level
Human lung carcinoma tissue microarray (TMA) slides were purchased from US Signal intensity from five fields of each tissue sample was scored by their staining color as follows: 0 (no immunostaining), 1 (light brown), 2 (medium brown) and 3 (dark brown). Two scores for each tissue sample were combined to evaluate the relative intensity and expression percentage of MIG-7 in each tissue sample.
Statistics
All statistical comparisons were made with two-tailed tests. The survival time was assessed using Kaplan-Meier curves and tested for significance by the log-rank test.
Statistical evaluation was performed using GraphPad Prism version 5.0 for Microsoft Windows (GraphPad Software, La Jolla, CA). Differences between groups were considered statistically significant at *P < 0.05, **P < 0.01 or ***P < 0.0001. Supplementary Fig. S1A ). To examine the potential relationship between COX-2, MIG-7 protein and cell invasiveness, we treated these lung cancer cells with COX-2-specific inhibitor NS398 or COX-2 siRNA (siCOX2) and found that it inhibited MIG-7 protein (by 2-4.5-fold) and decreased epithelial-mesenchymal transition (EMT) as indicated by a 2-4.5-fold increase in the level of epithelial cell marker E-cadherin and a 3-4.5-fold decrease in the level of mesenchymal cell marker vimentin (Fig. 1A and 1B) . siCOX2 also decreased PGE2, MMP-2 activity and migration/invasion by 2-4.5-fold in lung cancer cells ( Supplementary Fig. S1B-S1D ). In contrast, overexpressing COX-2 by transfection with pCOX-2 plasmids (pCOX2) increased COX-2 together with MIG-7 protein, PGE2, EMT, MMP-2 activity and migration/invasion by 2-3.5-fold in lung cancer cells (Fig. 1C and 1D ). MIG-7 knockdown (+siMIG7-1 or +siMIG7-2) attenuated the effect of COX-2 overexpression on MIG-7, EMT, MMP-2 and the migration/invasion of the cells by 30-60%, but did not affect expression level of COX-2 and PGE2 (Fig. 1C and 1D, Supplementary Fig. S1E and S1F).
PGE2-mediated EP4/Akt/GSK-3β signaling increases MIG-7 protein level to upregualte EMT and cell migration/invasion
The binding of PGE2 to EP receptors promotes colorectal cancer growth and progression (8, 25) . We found that overexpressing COX-2 in lung cancer cells MMP-2 activity and cancer cell migration/invasion were dependent on EP4 but not EP1 or EP2, as they were completely reversed by treatment of EP4 antagonist AH23848 or EP4 siRNA (siEP4) (Fig. 2A, 2B, Supplementary Fig. S2B and S2C ) but not by treatment of EP1 siRNA or EP2 siRNA.
Activation of PGE2-EP4 signaling stimulates the PI3K/Akt and ERK1/2 signaling cascades (8) (9) (10) (11) 25) . In this study, we found that PGE2 treatment of lung cancer cells for 40-60 min activated Akt by phosphorylation at serine 473, ERK1/2 by phosphorylation at threonine 185 and tyrosine 187 and inactivated GSK-3β by phosphorylation at serine 9 ( Supplementary Fig. S2D ). Overexpressing constitutively active Akt with dominant-active Akt plasmids (pAkt-DA) increased MIG-7 protein, EMT, MMP-2 activity, and cell migration and invasion by 2-3-fold ( Fig. 2C and 2D ).
Knockdown of MIG-7 attenuated effects of Akt overexpression on EMT, MMP-2 activity and cell invasion (by 30-60%) but not phosphorylation of GSK-3β ( Fig. 2C and 2D), indicating that MIG-7 is the downstream target of Akt/ GSK-3β signaling.
Activation of Akt/GSK-3β signaling enhances β-catenin-TCF-4/LEF-1 signaling cascade to elevate MIG-7 protein level
In some cancer cells inactivation of GSK-3β by phosphorylation at serine 9 has been shown to increase the accumulation of nuclear β-catenin which associates with TCF/ LEF to turn on Wnt signaling (26, 27) 
activity of TOPflash/FOPflash up to 45-fold that was accompanied with 11-fold increase in MIG-7 transcription in the lung cancer cells (Supplementary Fig. S3A ).
We further transfected A549 cells with dominant active (non-phosphorylated S9A-GSK-3β mutant) and dominant negative (kinase deficient K85A-GSK-3β mutant) plasmids (29) to examine whether they can regulate Wnt signaling and MIG-7 level.
Our results showed that constitutive overexpression of active GSK-3β by transfection of S9A-GSK-3β plasmids (pGSK3β-DA) downregulated phosphorylation of GSK-3β and attenuated accumulation of β-catenin, TOPflash reporter activity, and MIG-7 expression by 60-75% under PGE2 stimulation (Fig. 3A) . Transfection of K85A-GSK-3β plasmids (pGSK3β-DN), on the other hand, resulted in 2-4-fold increase in levels of β-catenin and MIG-7 proteins as well as around 40-fold increase in TOPflash reporter activity in lung cancer cells (Fig. 3A) . In addition, increase of β-catenin by transfection of active form of β-catenin (pβ-catenin-S33A) enhanced TOPflash reporter activity by 45-fold and MIG-7 expression more than 2-fold in A549 cells (Fig. 3B) . These results demonstrated activation of Wnt signaling and induction of MIG-7 expression by phosphorylated GSK-3β
Ser9 in lung cancer cells
Transfection with TCF-4 plasmids (pTCF4; 0.5-2 µg), LEF-1 plasmids (pLEF1; 0.5-2 µg) or both pTCF4 and pLEF1 plasmids enhanced MIG-7 transcription and expression up to 4-fold in a dose-dependent manner (Fig. 3C ). PGE2 increased transcription and expression of MIG-7 protein as well as β-catenin level ( Fig. 3D and Supplementary Fig. S3B ) up to 3-fold. The PGE-2-mediated increase of MIG-7
protein was attenuated partially (47%) by transfection with either TCF-4 siRNA (siTCF4) or LEF-1 siRNA (siLEF1) and abolished by combination of siTCF4 and siLEF1 ( Supplementary Fig. S3B ). These results suggest that PGE2 activates Akt/GSK-3β signaling to increase MIG-7 protein via enhancement of the 
β-catenin/LEF/TCF signaling cascade.
Elevation of MIG-7 protein level sustains phosphorylation of Akt, GSK-3β and ERK1/2 via inactivating PP2A
To further understand why elevation of MIG-7 protein level may be pivotal for the effects on the COX-2/PGE2 and PI3K/Akt/GSK-3β signaling cascade, we undertook time-course analysis. Our results showed that in parental control cells or cells transfected only with scrambled siRNA control (siCont), PGE2 treatment increased phosphorylation of Akt, GSK-3β and ERK1/2 by 4-6-fold within 1 hour, which then declined to the control level at 2 hours after treatment ( Fig. 4A and Supplementary   Fig. S4A ). MIG-7 protein level was not elevated until 12 hours after PGE2 treatment and reached a 4-fold plateau at 24-31 hours. After elevation of MIG-7 protein level, phosphorylation of Akt, GSK-3β and ERK1/2 was increased again and sustained at significantly high levels ( Fig. 4A and Supplementary Fig. S4A ). In comparison, in MIG-7 knockdown cells, even though phosphorylation of Akt, GSK-3β and ERK1/2 increased in 1 hour and declined to control level at 2 hours after PGE2 treatment in the same manner as control cells or siCont-transfected cells (Fig. 4B and Supplementary Fig. S4B ), increase in MIG-7 protein level after 12 hours or later was attenuated and so was phosphorylation of Akt, GSK-3β and ERK1/2 ( Fig. 4B and Supplementary Fig. S4B ).
Phosphorylation of Akt, GSK-3β and ERK1/2 is negatively regulated by phosphatases notably PP2A which accounts for the majority of serine-threonine phosphatase activity in eukaryotic cells (30) . We thus examined whether MIG-7 inactivates PP2A to sustain phosphorylation of Akt, GSK-3β and ERK1/2. By using methods to determine the interaction of PP2A with Akt and assay the PP2A phosphatase activity (31), we found that in PGE2-treated cancer cells, the amount of Akt associated with PP2A regulatory unit B55-α and the phosphatase activity of PP2A were maintained at the same levels before the elevation of MIG-7 protein level ( Supplementary Fig. S5A and S5B ). Twelve hours after PGE2 treatment, the 2.5-fold increase in MIG-7 protein level was accompanied with a 55% decrease in PP2A activity and a 45% decline in the amount of Akt associated with B55-α ( Supplementary Fig. S5A and S5B) . Knockdown of MIG-7 in PGE2-treated cancer cells reversed the decline in the amount of Akt associated with B55-α and restored the activity of PP2A ( Supplementary Fig. S5C and S5D ).
Overexpression of MIG-7 increases anchorage-independent growth and invasive ability of lung cancer cells
Knockdown of MIG-7 in lung cancer cells attenuated COX-2/PGE2 and
Akt-mediated EMT (Fig. 1C, 2C , 2D, 4B and Supplementary Fig. S1E, S4B ), a central tumorigenic process related to cellular migration/invasion and metastasis (32) . Our results showed that MIG-7 overexpression upregulated activities of migration and invasion and increased growth ability of lung cancer cells (A549, H1299 and CL1-0) in soft agar by 2-fold (Fig. 5A) . Knockdown of MIG-7 with MIG-7 siRNA (siMIG7-1 or siMIG7-2) in highly invasive CL1-5 human lung cancer cells decreased cell migration and invasion as well as clone-forming ability in soft agar by 40-55% ( (Fig. 5C and Supplementary Fig. S5E ). (Fig. 7) . 
DISCUSSION
Agonist of EP1 (ONO-DI-004) but not EP2, EP3 or EP4 was reported to increase invasion of hepatocellular carcinoma (33) . Since PGE2 receptors transactivate EGFR and MET, it has been proposed that there is a cross-talk between the COX-2/PGE2/EP1 and EGFR/c-Met signaling pathways that coordinately regulate human HCC cell invasion (33) . In this study, we found, however, that the effects of COX-2 and PGE2 on EMT, MIG-7 protein level, MMP-2 and cancer cell migration/invasion were reversed by inhibition of EP4 ( Fig. 2A, 2B , Supplementary showed that elevation of MIG-7 was associated with increase of EMT and phosphorylation of Akt, GSK-3β and ERK which occurred several hours before Twist induction ( Fig. 4A and Supplementary Fig. S4 ). As variation in MIG-7 protein level did not affect COX-2 and PGE2 level (Fig. 1C and Supplementary S1E) and elevation in MIG-7 protein level by 2.5-fold was accompanied by a 55% decrease in the activity of PP2A ( Supplementary Fig. S5A and S5B) , a negative regulator of Akt phosphorylation, it is most likely that MIG-7 mediates sustainment of Akt, GSK-3β and ERK1/2 phosphorylation primarily, if not exclusively, via this inactivating effect on PP2A. To what extent Twist and other phosphatases contribute to the PGE2-mediated phosphorylation of Akt, GSK-3β and ERK1/2 remains to be elucidated. 
MIG-7 activates MT1-MMP to regulate EMT and has been reported to be required for metastasis (19, (36) (37) (38) . Our results demonstrate that MIG-7 protein facilitates EMT and metastasis of lung cancer cells resulting in the death of animals bearing these cancer cells (Fig. 5 and 6 ). Since MT1-MMP regulates MMP-2 activation (39), it is likely that the increase of up to 2-fold MMP-2 activity by COX-2/PGE2 (Fig. 1D and Supplementary Fig. S1F ) in lung cancer cells is at least in part through effect of MIG-7 on MT1-MMP.
In this study, we found that siMIG7 reduced phosphorylation of serine 473 in Akt and Thr 185/Tyr 187 in ERK1/2 in lung cancer cells (Fig. 4) . This result is consistent with the report of MIG-7-specific shRNA effects in endometrial carcinoma cell lines (19) . Our finding of a positive correlation between MIG-7 protein level and malignant phenotypes and advanced stages of lung cancer (Fig. 7) is also consistent with that found in breast cancer tissue array (19) .
Overexpressing and/or knockdown of MIG-7 in A549, CL1-0 and CL1-5 cells demonstrate that MIG-7 promotes lung cancer metastasis in vivo (Fig. 6,   Supplementary Fig. S6 and Fig. S7 ). In addition, we have recently found that EMT and migration/invasion of other kinds of human cancers such as cervical HeLa cancer cells were promoted by overexpressing COX-2 and these effects of COX-2 were attenuated by 35-55% under MIG-7 knockdown. MIG-7 protein might thus play an important role in invasion/metastasis of a variety of cancers.
Since MIG-7 is rarely found in normal cells ( Fig. 7 and Supplementary Fig. S1A ) (16) (17) (18) (19) and change in MIG-7 level did not affect COX-2 and PGE2 level (Fig. 1C and Supplementary Fig. S1E ), whereas, knockdown of MIG-7 attenuated the effects of COX-2/PGE2 and Akt signaling on EMT, MMP2 and cancer cell migration/invasion by 30-60% (Fig. 1C, 1D , 2C, 2D and Supplementary Fig. S1E and S1F), inhibiting 
